QDELQDELHealthcare · Medical Devices

QDEL Stock Forecast: QuidelOrtho Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.32
−6.73% on the day

The 3 Wall Street analysts covering QuidelOrtho Corp. hold a median 12-month price target of $13 — +56.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$570.9M
Ticker Nerd rank
48/ 100
Median analyst target
$13
Analysts covering
3
Revenue$630.9M+2.8% y/y
Operating income−$15.3M
Net income−$92.9M
Free cash flow−$136.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.5%
1M
−41.4%
YTD
−70.9%
1Y
−61.0%
From 52W high
−76.5%
From 52W low
0.0%
$8
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores QuidelOrtho Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
48/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
86
Accruals
72
Growth
62
Quality
59
Revisions
43
Volatility
33
Issuance
31
Momentum
16

Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (16): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

QDEL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QDEL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26QDELHigh $20Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1
Buy
1
Hold
1
Sell
$12
Low
$13
Median
$20
High

The green dot is the last close — the median target sits +56.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 July 2026CitigroupMaintainsNeutral$13 → $18
1 July 2026JP MorganMaintainsUnderweight$11 → $12
7 May 2026JefferiesDowngradeHold—
6 May 2026CitigroupMaintainsNeutral—
10 Apr 2026UBSMaintainsNeutral—
12 Feb 2026CitigroupMaintainsNeutral—
21 Jan 2026UBSMaintainsNeutral—
7 Nov 2025JP MorganMaintainsUnderweight—
6 Nov 2025UBSMaintainsNeutral—
7 Oct 2025CitigroupDowngradeNeutral—
7 Aug 2025UBSMaintainsNeutral—
6 Aug 2025CitigroupMaintainsBuy—
8 May 2025JefferiesUpgradeBuy—
8 May 2025UBSMaintainsNeutral—
21 Apr 2025JP MorganMaintainsUnderweight—
13 Feb 2025RBC CapitalMaintainsOutperform—
13 Feb 2025UBSMaintainsNeutral—
11 Dec 2024CitigroupUpgradeBuy—
10 Dec 2024JefferiesInitiatesHold—
19 Sept 2024UBSUpgradeNeutral$42 → $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QDEL.

Market Radar

This page is one stock. Monday covers all of them.

QDEL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

QDEL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, QuidelOrtho Corp. returned −61.0% against +6.9% for the S&P 500, dividends included.

QDEL vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26QDELS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QDEL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−14.5%
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.2×

Cheaper than 89% of US stocks

Price / book
0.3×

Cheaper than 91% of US stocks

EV / EBITDA
7.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
43.3%

Higher than 54% of US stocks

Operating margin
0.2%

Higher than 43% of US stocks

Net margin
—
Returns & dividend
Return on equity
−19.3%

Higher than 32% of US stocks

Return on assets
0.0%

Higher than 43% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • QuidelOrtho Corp. has a market value of $570.9M and an enterprise value of $3.5B.

  • Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 2.8% year on year.

  • Net income over the same four quarters: −$1.0B, a −39.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$15.41.

  • Free cash flow in the twelve months to 30 June 2026: −$211.2M.

  • Shares outstanding: 68.3M.

  • forward P/E: 6.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • QuidelOrtho Corp. employs 6,500 people — $411K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

QDEL and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
QDELQuidelOrtho Corp.$570.9M48
TCMDTactile Systems Technology, Inc.$577.4M97
SGHTSight Sciences, Inc.$549.8M85
DCTHDelcath Systems, Inc.$648.7M98
PACBPacific Biosciences of California, Inc.$492.3M68
AVRAnteris Technologies Global Corp.$485.2M25
RCELAVITA Medical, Inc.$483.1M85

Take a look at QDEL’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own QuidelOrtho Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about QDEL

What is the QDEL stock price forecast for 2026-2027?

The 3 Wall Street analysts covering QuidelOrtho Corp. have a median 12-month price target of $13, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QDEL stock a buy right now?

Of the 3 analysts covering QuidelOrtho Corp., 1 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks QuidelOrtho Corp. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QDEL?

As at 21 Nov 2026, QuidelOrtho Corp. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).

Will QDEL stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +56.3% from the last close, and Ticker Nerd's factor model ranks QuidelOrtho Corp. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QDEL stock forecast for 2030?

No analyst covering QuidelOrtho Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QDEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.

How has QDEL stock performed over the past year?

QuidelOrtho Corp. returned -61.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does QuidelOrtho Corp. do?

QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine.

Company

About QuidelOrtho Corp.

QuidelOrtho Corporation is a diagnostic healthcare company that develops, manufactures, and markets testing solutions used across the healthcare continuum. The company focuses on in vitro diagnostics, with products and platforms spanning immunoassay, molecular testing, clinical chemistry, point-of-care testing, labs, and transfusion medicine. Its offerings are designed to support disease detection, monitoring, and clinical decision-making in settings ranging from hospitals and reference laboratories to blood banks and other care environments. QuidelOrtho serves a global market and plays an important role in providing tools that help clinicians identify infections, manage chronic conditions, and support transfusion safety. Headquartered in San Diego, California, QuidelOrtho Corporation combines broad diagnostic expertise with a diversified portfolio that addresses both routine and specialized testing needs in modern healthcare.

CEO Mr. Brian J. Blaser · 6,500 employees · United States · https://www.quidelortho.com